.elementor-panel-state-loading{ display: none; }



Alzheimer’s app could be key for newly diagnosed patients

A personalized diagnosis for those diagnosed with Alzheimer’s disease may soon be just a click away.

Researchers at the University Medical Center Amsterdam announced that they have developed a prototype app based on a model that predicts five-year intellectual decline in patients with Alzheimer’s disease.

The model is inspired by detailed information collected from nearly 1,000 people with Alzheimer’s disease, the most common type of dementia. Data includes age, sex and cognitive test scores, as well as information from MRI scans and markers of disease activity found in cerebrospinal fluid.

“This really gives you a personalized forecast.” Peter van der Velea physician and researcher at the Amsterdam Alzheimer’s Center, said of the model:

The next step is to develop a user-friendly app using feedback from patients, families and experts. Half Point – stock.adobe.com

The app prototype has been used in scientific research and the next step is to develop a user-friendly app with feedback from patients, families and specialists.

The findings were released Wednesday. Journal of Neurology.

According to the Centers for Disease Control and PreventionCurrently, 5.8 million Americans live with Alzheimer’s disease or related dementias, and that number is projected to rise to 14 million by 2060.

Most patients are over 65 years old.

In the United States, 5.8 million people have Alzheimer’s disease or related dementias, and that number is projected to rise to 14 million by 2060. Andrey – stock.adobe.com

After diagnosis, the first question many people ask is, “What’s going to happen now?” While this model doesn’t provide a definitive answer, it claims to be able to predict the course of the disease over a five-year period.

“Previous research has shown that people still want information about their prognosis, even if that information is uncertain, so an app powered by our predictive model could fill an important need,” van der Veele said.

Wiesje van der Vliere, research director at the Amsterdam Alzheimer’s Centre, said the model could explain the potential consequences of treatment options such as lifestyle changes and drug use.

“This will provide a starting point for a discussion between doctor, patient and family about the pros and cons of treatment so that appropriate decisions can be made together,” van der Vliere said.

There is no cure for dementia, but medications can help manage symptoms and slow the progression of the disease.

After being diagnosed, the first question many Alzheimer’s patients ask is, “What’s going to happen now?” Malik E/peopleimages.com – stock.adobe.com

Last week, the U.S. Food and Drug Administration approved Eli Lilly & Co.’s donanemab injection, given monthly to adults with early-stage Alzheimer’s disease.

The drug, sold under the brand name Kisunra, is thought to slow cognitive decline by removing protein clumps in the brain.

Meanwhile, British scientists recently announced a new test that they claim can predict the onset of dementia up to nine years before an official diagnosis is made.